Hexarelin (5mg) protocols center on this synthetic hexapeptide classified as a growth hormone secretagogue, known for stimulating endogenous growth hormone (GH) release via the ghrelin receptor (GHS-R1a). It has been studied for its potential effects on muscle recovery, body composition, and cardiovascular support. This guide outlines a subcutaneous administration approach optimized for the 5 mg vial format.
Concise summary of the subcutaneous regimen.
Suggested approach for the 5 mg vial format.
Hexarelin is a potent growth hormone secretagogue that binds to the ghrelin receptor (GHS-R1a) in the pituitary gland and hypothalamus. This binding stimulates pulsatile release of endogenous growth hormone without directly supplying exogenous GH.
Increased GH secretion may support downstream effects such as elevated IGF-1 production, enhanced protein synthesis, improved fat metabolism, and tissue repair processes. Unlike some other secretagogues, Hexarelin has also been studied for potential cardioprotective effects in preclinical models, including support for cardiac contractility and reduced ischemic damage.
Observations based on preclinical and early research literature.
Potential Benefits:
Possible Side Effects: